Pretreatment with PDE5 inhibitors, ED severity, and presence or absence of diabetes and BPH had an impact on treatment effectiveness; however, age and presence of hypertension, CVD, dyslipidemia, or ED etiology did not affect IIEF in this cohort. The gene discussed is PDE5A; the disease is diabetes mellitus.